- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01957618
The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy (CTEAM)
Hepatitis B virus (HBV) infection is a global health problem, especially in the endemic area like Taiwan, where there are more than 3 million chronic hepatitis B carriers. Patients with chronic HBV infection are at increased risk of developing cirrhosis, which may have disastrous complications, including hepatic decompensation, and hepatocellular carcinoma (HCC). The liver cirrhosis related complications accounts for the 8th leading cause of deaths in Taiwan; whereas, the HCC is the 2nd leading cause of deaths among all cancers. Therefore, it is prudent to develop strategies to prevent or halt the progression of liver cirrhosis.
For HBV patients who have already had cirrhosis, the main treatment objective is to reduce their risk of complications. A large-scale multicenter clinical trial showed that viral suppression using lamivudine in patients with advanced fibrosis effectively decreases the risk of HCC and liver-related complications. This study highlights the importance to treat HBV-related cirrhosis patients; however, several issues remain to be addressed.
The first issue is that this clinical trial only enrolled patients with positive HBeAg or HBV-DNA level >1.4 x105 IU/mL. However, the current recommended threshold for cirrhotic patients to start anti-viral treatment is 2000 IU/mL. Whether anti-HBV therapy benefits cirrhotic patients in this level is still unclear. Second, lamivudine was used in this clinical trial; however, the high resistant rate of lamivudine during treatment probably lowers its protective effect against HCC. Whether a more potent anti-HBV agent with extremely low resistance profile, entecavir, is more beneficial to HBV-related cirrhotic patients is also unclear.
The Bureau of National Health Institute launched the reimbursement program for anti-HBV therapy since 2003 and extended this program to cirrhotic patients with HBV DNA level > 2000 IU/mL for long-term use since Aug, 2010. Taking this advantage, we may explore the above-mentioned clinical questions more easily.
To address these issues, we will first retrospectively collect a cohort of HBV-related cirrhosis patients. All the patients will be enrolled from the time before oral anti-HBV therapy is widely used. We will determine their baseline serum HBV-DNA levels using the stored sera and enrolled those with baseline HBV-DNA levels higher than 2000 IU/mL as our historical controls. Second, we will enroll a retrospective cohort of HBV-related cirrhotic patients from 2008 who had HBV-DNA levels higher than 2000 IU/mL and received indefinite therapy of entecavir. By comparing these two cohorts, we will be able to clarify whether indefinite viral suppression by entecavir is beneficial for the cirrhotic patients.
With comprehensive analysis, we wish to document that re-setting the risk level of HBV DNA from 140,000 IU/mL to 2,000 IU/mL is more beneficial for HBV-related cirrhotic patients and long-term entecavir does lower the risk of HCC further. These lines of evidence will assist in delivering appropriate and more aggressive treatment for these high-risk patients.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Taipei, Taiwán
- National Taiwan University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria for treatment group:
- Age older than 20 years old.
- HBsAg (+) > 6 months
- Baseline serum HBV DNA ≧ 2000 IU/mL (10,000 copies/mL)
- Liver cirrhosis (Child A) before or at enrollment, diagnosed by 1). Liver biopsy(Metavir F4 or Ishak > F5) or 2). Ultrasonographic evidence of cirrhosis with signs of portal hypertension (splenomegaly or presence of esophageal or gastric varices)
- Receiving long-term anti-HBV therapy
Inclusion Criteria for control group:
- Age older than 20 years old.
- HBsAg (+) > 6 months
- Baseline serum HBV DNA ≧ 2000 IU/mL (10,000 copies/mL)
- Liver cirrhosis (Child A) before or at enrollment, diagnosed by 1). Liver biopsy(Metavir F4 or Ishak > F5) or 2). Ultrasonographic evidence of cirrhosis with signs of portal hypertension (splenomegaly or presence of esophageal or gastric varices)
- without receiving treatment
Exclusion Criteria:
- . Co-infection of HCV (anti-HCV (+)) or HIV
- . Alcoholism (alcohol consumption > 20 gm/day)
- . Serological evidence suggestive of autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease and hemochromatosis
- . Liver decompensation (Child-Pugh classification of B or C)
- . Evidence of HCC at study entry
- . Pregnant women
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Treatment group
liver cirrhosis group who received indefinite anti-viral treatment
|
Historical control group
Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
hepatocellular carcinoma
Periodo de tiempo: within a 10-year follow-up.
|
within a 10-year follow-up.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jia-Horng Kao, PhD, National Taiwan University Hospital
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades del HIGADO
- Hepatitis, Viral, Humana
- Infecciones por Hepadnaviridae
- Infecciones por virus de ADN
- Infecciones por enterovirus
- Infecciones por Picornaviridae
- Hepatitis Crónica
- Fibrosis
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B Crónica
- Cirrosis hepática
Otros números de identificación del estudio
- 201110057RC
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hepatitis B Virus-Related Hepatocellular Carcinoma
-
Tasly Tianjin Biopharmaceutical Co., Ltd.TerminadoVirus de la hepatitis B (VHB)Porcelana
-
Enanta Pharmaceuticals, IncTerminadoInfección crónica por el virus de la hepatitis BNueva Zelanda
-
Tasly Tianjin Biopharmaceutical Co., Ltd.Desconocido
-
Bristol-Myers SquibbTerminadoVirus de la hepatitis B crónica, pediátricoEstados Unidos, Corea, república de, Taiwán, Reino Unido, Bélgica, Canadá, Federación Rusa, Argentina, Alemania, Grecia, India, Israel, Polonia, Rumania
-
Hoffmann-La RocheTerminadoInfección por el virus de la hepatitis BReino Unido, Hong Kong, Corea, república de, Taiwán, Polonia, Bulgaria, Nueva Zelanda
-
Brii Biosciences LimitedVir Biotechnology, Inc.Activo, no reclutandoInfección crónica por el virus de la hepatitis BSingapur, Tailandia, Australia, Porcelana, Corea, república de
-
National Taiwan University HospitalPharmaEssentiaReclutamientoInfección crónica por el virus de la hepatitis BTaiwán
-
California Pacific Medical Center Research InstituteUniversity of California, San FranciscoActivo, no reclutando
-
National Institute of Diabetes and Digestive and...ReclutamientoVirus de la Hepatitis B Crónica (Hbv)Estados Unidos
-
Yangshengtang Co., LtdAún no reclutandoInfección crónica por el virus de la hepatitis B